HomeProductsBioactive CompoundsCell CycleCDKPha-793887
Chemical structure of CAS 718630-59-2

Pha-793887

CAS No.718630-59-2
MDL No.N/A
MFC19H31N5O2
MW361.50
InChI KeyHUXYBQXJVXOMKX-UHFFFAOYSA-N
CUSTOM SYNTHESIS

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

N-[6,6-dimethyl-5-[(1-methylpiperidin-4-yl)oxomethyl]-1,4-dihydropyrrolo[3,4-c]pyrazol-3-yl]-3-methylbutanamide is a piperidinecarboxamide.

CAS No.718630-59-2
Product NamePha-793887
Heavy Atom Count26Rotatable Bond Count4
Atom Stereo Count0Bond Stereo Count0
HBA4HBD2
TPSA81.330 ŲCharge0
Exact Mass361.24778Complexity686.10
pKa5.875XLogP2.313

Related Articles

Studies related to this compound and its mechanism of action

A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors.

Cell cycle (Georgetown, Tex.) • Vol. 10, Issue 6 • 2011
PMID: 21368575DOI: 10.4161/cc.10.6.15075

An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridae.

Cell cycle (Georgetown, Tex.) • Vol. 10, Issue 1 • 2011
PMID: 21200142DOI: 10.4161/cc.10.1.14445

Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study.

Molecular cancer therapeutics • Vol. 9, Issue 5 • 2010
PMID: 20423997DOI: 10.1158/1535-7163.MCT-09-1163

Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.

Bioorganic & medicinal chemistry • Vol. 18, Issue 5 • 2010
PMID: 20153204DOI: 10.1016/j.bmc.2010.01.042

Documentation